Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 005111109 since 12/18/2024.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
James E. Flynn
13D/A
|
9.1% |
1/28/2025
Event 1/27/2025
|
|
| Deerfield Mgmt III, L.P. | 5.4% | ||
| Deerfield Private Design Fund III, L.P. | 5.4% | ||
| Deerfield Mgmt, L.P. | 4.9% | ||
| Deerfield Partners, L.P. | 4.9% | ||
| Deerfield Management Company, L.P. | 9.1% | ||
| James E. Flynn | 9.1% | ||
| Under 5%, or checked the "5 percent or less" box (1) | |||
|
Advent Life Sciences LLP
13G/A
|
0.1% |
2/17/2026
Event 7/9/2025
|
|
| Advent Life Sciences LLP | 0% | ||
| Advent Life Sciences Fund I LP | 0% | ||
| Shahzad Malik | 0.1% | ||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q2 | 1 | 2.00 k | $4.00 |
| 2025 Q1 | 1 | 2.00 k | $85.00 |
| 2024 Q4 | 1 | 3.00 k | $165.00 |
| 2024 Q3 | 1 | 3.00 k | $252.00 |
| 2024 Q2 | 1 | 6.40 k | $227.00 |
| 2024 Q1 | 26 | 6.63 M | $1.25 M |
| 2023 Q4 | 34 | 7.02 M | $1.42 M |
| 2023 Q3 | 31 | 8.59 M | $5.98 M |
| 2023 Q2 | 38 | 9.15 M | $8.13 M |
| 2023 Q1 | 42 | 9.23 M | $6.96 M |
| 2022 Q4 | 44 | 9.31 M | $10.7 M |
| 2022 Q3 | 43 | 10.4 M | $9.11 M |
| 2022 Q2 | 52 | 11.2 M | $12.5 M |
| 2022 Q1 | 69 | 16.0 M | $22.3 M |
| 2021 Q4 | 77 | 17.8 M | $60.8 M |
| 2021 Q3 | 75 | 20.2 M | $179 M |
| 2021 Q2 | 67 | 23.5 M | $399 M |
| 2021 Q1 | 69 | 22.8 M | $305 M |
| 2020 Q4 | 66 | 21.0 M | $603 M |
| 2020 Q3 | 70 | 19.4 M | $578 M |